Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00086203
Recruitment Status : Completed
First Posted : June 29, 2004
Last Update Posted : March 25, 2015
Information provided by:
FDA Office of Orphan Products Development

Brief Summary:
The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Drug: Talabostat mesylate (PT-100) tablets Drug: Rituximab Phase 2

Detailed Description:
Completion date provided represents the completion date of the grant per OOPD records

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Completion Date : September 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Men or women ≥18 years of age
  • Histopathologically confirmed diagnosis of B-CLL expressing surface CD20 of any detectable intensity
  • Rai Stage III or IV. Rai Stages I and II with massive or progressive lymphadenopathy or hepatosplenomegaly.
  • Primary resistance to a fludarabine regimen (no PR or CR) or progressive disease within 1 year of a prior response
  • ECOG performance status 0, 1, or 2
  • Written informed consent


  • Therapy for CLL within 4 weeks of Study Day 1 (including chemotherapy, radiation, immunotherapy, cytokine or biologic [with the exception of hematopoietic growth factors]). Patients must have recovered from the adverse effects of prior therapy.
  • Known primary or secondary malignancy of the central nervous system
  • Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix
  • Serum creatinine >2.0mg/dL (>176 micromol/L)
  • AST or ALT ≥3 x the upper limit of normal (ULN)
  • Total bilirubin ≥1.5 x ULN (unless secondary to Gilbert's)
  • Positive serology for hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody)
  • Known positivity for HIV
  • Prior organ allograft
  • Concurrent comorbid medical conditions that, in the opinion of the investigator, preclude the safe delivery of the experimental treatment
  • Pregnant or nursing women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00086203

United States, Arkansas
University of Arkansas for Medical Science
Little Rock, Arkansas, United States, 72205
United States, Florida
Ocala Oncology Center
Ocala, Florida, United States, 34474
Gulfcoast Oncology Associates
St. Petersburg, Florida, United States, 33705
United States, Indiana
Indiana Oncology/Hematology Consultants
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Montana
Hematology/Oncology Centers of the Northern Rockies
Billings, Montana, United States, 59101
United States, Nevada
Nevada Cancer Institute
Las Vegas, Nevada, United States, 89135
United States, New York
Queens Medical Associates, PC
Fresh Meadows, New York, United States, 11365
Long Island Jewish Medical Center
New Hyde Park, New York, United States, 11040
NYU Medical Center
New York, New York, United States, 10016
James P. Wilmot Cancer Center/University of Rochester
Rochester, New York, United States, 14642
United States, North Carolina
Raleigh Hematology/Oncology Clinic
Cary, North Carolina, United States, 27511
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
United States, Oklahoma
Cancer Care Associates/Oklahoma City
Oklahoma City, Oklahoma, United States, 73112
Cancer Care Associates--Tulsa
Tulsa, Oklahoma, United States, 74136
United States, South Carolina
Cancer Centers of the Carolinas
Seneca, South Carolina, United States, 29672
United States, Texas
Texas Cancer Center/Abilene
Abilene, Texas, United States, 79606-5208
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Virginia
Virginia Oncology Associates-Lake Wright Cancer Center
Norfolk, Virginia, United States, 23502
Sponsors and Collaborators
Point Therapeutics Identifier: NCT00086203     History of Changes
Other Study ID Numbers: PTH-203
First Posted: June 29, 2004    Key Record Dates
Last Update Posted: March 25, 2015
Last Verified: August 2006

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents